Az Anthropic AI-modellje 35 000 ellenanyag-tervet készített egy hónap alatt

by EMMA KOPPELMAN | The National News Desk WASHINGTON (TNND) — In a new push to bring artificial intelligence deeper into drug development, Anthropic says its Claude model generated about 35,000 antibody designs in roughly a month for a potential food-allergy treatment. The work was conducted with biotech company Divergence Labs. In early tests, researchers identified designs that could bind to or dislodge IgE, a molecule involved in allergic reactions. Anthropic said three designs appeared to dislodge IgE more effectively than a standard medication. The teams’ next step is to try combining the designs into a drug. Anthropic also described work with five other organizations developing medicines. In a separate project, the company said Claude helped researchers design a shorter set of genetic instructions for a cancer treatment. Lab tests found the redesigned instructions helped immune cells produce about 10 times as many cancer-targeting receptors, Anthropic said. Beyond designing therapies, Anthropic said Claude is being used for tasks including reviewing manufacturing records and drafting regulatory documents. At Enveda, Anthropic said, Claude reduced human review time on a set of documents by 89%. The projects are early stage and largely preclinical, meaning the treatments have not yet reached human trials. Anthropic said it plans to expand the work.